The pharmacokinetics of silymarin is altered in patients with hepatitis C virus and nonalcoholic fatty liver disease and correlates with plasma caspase-3/7 activity

Drug Metabolism and Disposition

Volumn 36, Issue 9, 2008, Pages 1909-1916

  Schrieber, Sarah J ^a   Wen, Zhiming ^a   Vourvahis, Manoli ^a   Smith, Philip C ^a   Fried, Michael W ^b   Kashuba, Angela D M ^a   Hawke, Roy L ^a  

^a University of North Carolina   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; CASPASE 3; CASPASE 7; FLAVONOLIGNAN; INTERLEUKIN 6; SILICRISTIN; SILYBIN A; SILYBIN B; SILYBUM MARIANUM EXTRACT; SILYMARIN; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CASE REPORT; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; DRUG BLOOD LEVEL; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; HEPATITIS C VIRUS; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; LIVER CIRRHOSIS; MALE; NONALCOHOLIC FATTY LIVER; NORMAL HUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; SINGLE DRUG DOSE;

ADOLESCENT; ADULT; AGED; APOPTOSIS; AREA UNDER CURVE; CASPASE 3; CASPASE 7; COHORT STUDIES; FATTY LIVER; FEMALE; HALF-LIFE; HEPATITIS C; HUMANS; MALE; MIDDLE AGED; OXIDATIVE STRESS; SILYMARIN;

HEPATITIS C VIRUS; SILYBUM MARIANUM;

EID: 50049099550     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.107.019604     Document Type: Article

References (40)

1. Bantel H, Lügering A, Heidemann J, Volkmann X, Poremba C, Strassburg CP, Manns MP, and Schulze-Osthoff K (2004) Detection of apoptotic caspase activation in sera from patients with chronic HCV infection is associated with fibrotic liver injury. Hepatology 40:1078-1087.
2. Bantel H, Lügering A, Poremba C, Lugering N, Held J, Domschke W, and Schulze-Osthoff K (2001) Caspase activation correlates with the degree of inflammatory liver injury in chronic hepatitis C virus infection. Hepatology 34:758-767.
3. Barnes SN, Aleksunes LM, Augustine L, Scheffer GL, Goedken MJ, Jakowski AB, Pruimboom-Brees IM, Cherrington NJ, and Manautou JE (2007) Induction of hepatobiliary efflux transporters in acetaminophen-induced acute liver failure cases. Drug Metab Dispos 35:1963-1969.
4. Beckmann-Knopp S, Rietbrock S, Weyhenmeyer R, Böcker RH, Beckurts KT, Lang W, Hunz M, and Fuhr U (2000) Inhibitory effects of silibinin on cytochrome P-450 enzymes in human liver microsomes. Pharmacol Toxicol 86:250-256.
5. Buzzelli G, Moscarella S, Barbagli, Marena C, and Gentilini P (1994) Therapeutic effect of silipide in patients with chronic hepatic C non responders (NTs) to interferon (IFN) treatment. J Hepatol 21:S100.
6. Calabrese F, Pontisso P, Pettenazzo E, Benvegnù L, Vario A, Chemello L, Alberti A, and Valente M (2000) Liver cell apoptosis in chronic hepatitis C correlates with histological but not biochemical activity or serum HCV-RNA levels. Hepatology 31:1153-1159.
7. Cermak R and Wolffram S (2006) The potential of flavonolignans to influence drug metabolism and pharmacokinetics by local gastrointestinal mechanisms. Curr Drug Metab 7:729-744.
8. Congiu M, Mashford ML, Slavin JL, and Desmond PV (2002) UDP-Glucuronosyltransferase mRNA levels in human liver disease. Drug Metab Dispos 30:129-134.
9. Crocenzi FA and Roma MG (2006) Silymarin as a new hepatoprotective agent in experimental cholestasis: new possibilities for an ancient medication. Curr Med Chem 13:1055-1074.
10. Ferenci P, Dragosics B, Dittrich H, Frank H, Benda L, Lochs H, Meryn S, Base W, and Schneider B (1989) Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol 9:105-113.
11. Gordon A, Hobbs DA, Bowden DS, Bailey MJ, Mitchell J, Francis AJ, and Roberts SK (2006) Effects of silybum marianum on serum hepatitis C virus RNA, alanine aminotransferase levels and well-being in patients with chronic hepatitis C. J Gastroenterol Hepatol 21:275-280.
12. Guardigli M, Marangi M, Casanova S, Grigioni WF, Roda E, and Roda A (2005) Chemiluminescence quantitative immunohistochemical determination of MRP2 in liver biopsies. J Histochem Cytochem 53:1451-1457.
13. Hinoshita E, Taguchi K, Inokuchi A, Uchiumi T, Kinukawa N, Shimada M, Tsuneyoshi M, Sugimachi K, and Kuwano M (2001) Decreased expression of an ATP-binding cassette transporter, MRP2, in human livers with hepatitis C virus infection. J Hepatol 35:765-773.
14. Huber R, Futter I, and Lüdtke R (2005) Oral silymarin for chronic hepatitis C - a retrospective analysis comparing three dose regimens. Eur J Med Res 10:68-70.
15. Jacobs BP, Dennehy C, Ramirez G, Sapp J, and Lawrence VA (2002) Milk thistle for the treatment of liver disease: a systematic review and meta-analysis. Am J Med 113:506-515.
16. Kamisako T and Ogawa H (2007) Effect of bile duct obstruction on the expression of intestinal mRNA related to cholesterol and bile acid metabolism in the rat. J Gastroenterol Hepatol 22:125-131.
17. Kren V, Ulrichova J, Kosina P, Stevenson D, Sedmera P, Prikrylová V, Halada P, and Simánek V (2000) Chemoenzymatic preparation of silibin β-glucuronides and their biological evaluation. Drug Metab Dispos 28:1513-1517.
18. Kvasnicka F, Biba B, Sevcik R, Voldrich M, and Kratka J (2003) Analysis of the active components of silymarin. J Chromatogr A 90:239-245.
19. Lickteig AJ, Fisher CD, Augustine LM, Aleksunes LM, Besselsen DG, Slitt AL, Manautou JE, and Cherrington NJ (2007) Efflux transporter expression and acetaminophen metabolite excretion are altered in rodent models of non-alcoholic fatty liver disease. Drug Metab Dispos 35:1970-1980.
20. Lorenz D, Lücker PW, Mennicke WH, and Wetzelsberger N (1984) Pharmacokinetic studies with silymarin in human serum and bile. Methods Find Exp Clin Pharmacol 6:655-661.
21. Lucena MI, Andrade RJ, de la Cruz JP, Rodriguez-Mendizabal M, Blanco E, and Sánchez de la Cuesta F (2002) Effects of silymarin MZ-80 on oxidative stress in patients with alcoholic cirrhosis. Results of a randomized, double-blind, placebo-controlled clinical study. Int J Clin Pharmacol Ther 40:2-8.
22. Manna SK, Mukhopadhyay A, Van NT, and Aggarwal BB (1999) Silymarin suppresses TNF-induced activation of NF-kappa B, c-Jun N-terminal kinase, and apoptosis. J Immunol 163:6800-6809.
23. Mayer KE, Myers RP, and Lee SS (2005) Silymarin treatment of viral hepatitis: a systematic review. J Viral Hepat 12:559-567.
24. Morris ME and Zhang S (2006) Flavonolignan-drug interactions: effects of flavonolignans on ABC transporters. Life Sci 78:2116-2130.
25. Pár A, Róth E, Rumi G Jr, Kovács Z, Nemes J, and Mózsik G (2000) Oxidative stress and antioxidant defense in alcoholic liver disease and chronic hepatitis C. Orv Hetil 141:1655-1659.
26. Parés A, Planas R, Torres M, Caballeria J, Viver JM, Acero D, Panés J, Rigau J, Santos J, and Rodés J (1998) Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial. J Hepatol 28:615-621.
27. Polyak SJ, Morishima C, Shuhart MC, Want CC, Liu Y, and Lee DY (2007) Inhibition of T cell inflammatory cytokines, hepatocyte NF-kappaB signaling, and HCV infection by standardized silymarin. Gastroenterology 132:1925-1936.
28. Psotová J, Chlopciková S, Grambal F, Simánek V, and Ulrichová J (2002) Influence of silymarin and its flavonolignans on doxorubicin-iron induced lipid peroxidation in rat heart microsomes and mitochondria in comparison with quercetin. Phytother Res 16:S63-S67.
29. Rambaldi A, Jacobs BP, and Gluud C (2007) Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases. Cochrane Database Syst Rev 4:CD003620.
30. Rickling B, Hans B, Kramarczyk R, Krumbiegel G, and Weyhenmeyer R (1995) Two high-performance liquid chromatographic assays for the determination of free and total silibinin diastereomers in plasma using column switching with electrochemical detection and reversed-phase chromatography with ultraviolet detection. J Chromatogr B Biomed Appl 670:267-277.
31. Russo MW, Esposite S, Borwn RS Jr, Foulgar KC, and Jacobson IM (2001) Complementary alternative medicine (CAM) use amongst patients with chronic hepatitis C infection (HCV) (abstract). Gastroenterology 120:A409.
32. Saller R, Meier R, and Brignoli R (2001) The use of silymarin in the treatment of liver diseases. Drugs 61:2035-2063.
33. Schümann J, Prockl J, Kiemer AK, Vollmar AM, Bang R, and Tiegs G (2003) Silibinin protects mice from T cell-dependent liver injury. J Hepatol 39:333-340.
34. Seidel N, Volkmann X, Länger F, Flemming P, Manns MP, Schulze-Osthoff K, and Bantel H (2005) The extent of liver steatosis is chronic hepatitis C virus infection is mirrored by caspase activity in serum. Hepatology 42:113-120.
35. Tanamly MD, Tadros F, Labeeb S, Makld H, Shehata M, Mikhail N, Abdel-Hamid M, Shehata M, Abu-Baki L, Medhat A, et al. (2004) Randomised double-blinded trial evaluating silymarin for chronic hepatitis C in an Egyptian village: study description and 12-month results. Dig Liver Dis 36:752-759.
36. Velussi M, Cernigoi AM, De Monte A, Dapas F, Caffau C, and Zilli M (1997) Long-term (12 months) treatment with an anti-oxidant drug (silymarin) is effective on hyperinsulinemia, exogenous insulin need and malondialdehyde levels in cirrhotic diabetic patients. J Hepatol 26:871-879.
37. Wagner M, Zollner G, Fickert P, Gumhold J, Silbert D, Fuchsbichler A, Gujral JS, Zatloukal K, Denk H, Jaeschke H, et al. (2005) Hepatobiliary transporter expression in ICAM-/- and lpr mice after common bile duct ligation is independent of the degree of inflammation and oxidative stress. Drug Metab Dispos 35:1694-1699.
38. Wen Z, Dumas TE, Schrieber SJ, Hawke RL, Fried MW, and Smith PC (2008) Pharmacokinetics and metabolic profile of free, conjugated and total silymarin flavonolignans in human plasma after oral administration of milk thistle extract. Drug Metab Dispos 36:65-72.
39. Weyhenmeyer R, Mascher H, and Birkmayer J (1992) Study on dose-linearity of the pharmacokinetics of silibinin diastereomers using a new stereospecific assay. Int J Clin Pharmacol Ther Toxicol 30:134-138.
40. Wu JW, Lin LC, Hung SC, Lin CH, Chi CW, and Tsai TH (2008) Effect of silibinin on the pharmacokinetics of pyrazinamide and pyrazinoic acid in rats. Drug Metab Dispos 36:589-596.